Somerset Group LLC maintained its position in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,771 shares of the biopharmaceutical company’s stock at the end of the second quarter. Celgene Corporation accounts for approximately 1.3% of Somerset Group LLC’s holdings, making the stock its 20th biggest holding. Somerset Group LLC’s holdings in Celgene Corporation were worth $1,399,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. State Street Corp increased its position in Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after purchasing an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp increased its position in Celgene Corporation by 4.9% during the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after purchasing an additional 472,067 shares in the last quarter. American Century Companies Inc. increased its position in Celgene Corporation by 4.4% during the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after purchasing an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. increased its position in Celgene Corporation by 15.7% during the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after purchasing an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC increased its position in Celgene Corporation by 24.1% during the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after purchasing an additional 892,392 shares in the last quarter. Institutional investors and hedge funds own 79.24% of the company’s stock.

WARNING: “Somerset Group LLC Continues to Hold Holdings in Celgene Corporation (CELG)” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/somerset-group-llc-continues-to-hold-holdings-in-celgene-corporation-celg/1644929.html.

Shares of Celgene Corporation (CELG) opened at 121.33 on Friday. The stock has a 50 day moving average of $140.79 and a 200 day moving average of $130.41. The stock has a market cap of $94.92 billion, a P/E ratio of 37.58 and a beta of 1.88. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the previous year, the business posted $1.44 EPS. The company’s quarterly revenue was up 18.7% on a year-over-year basis. On average, analysts forecast that Celgene Corporation will post $7.33 EPS for the current year.

A number of equities analysts recently issued reports on CELG shares. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded shares of Celgene Corporation from a “hold” rating to a “strong-buy” rating and set a $149.76 price objective for the company in a research report on Tuesday, July 4th. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 6th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $139.00 price objective on shares of Celgene Corporation in a research report on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have assigned a buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and a consensus target price of $150.43.

In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,233 shares of company stock worth $6,268,259. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.